Nov 22 2024 This Week in Cardiology
Episode description
An AHA review: the OPTION, SUMMIT, VANISH 2, SARAH, and CLEAR trials are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
I. OPTION Trial
For AF, LAA Rivals Anticoagulants After Ablation
https://www.medscape.com/viewarticle/af-laa-rivals-anticoagulants-after-ablation-2024a1000l7n
4 Reasons to Question Percutaneous Left Atrial Appendage Closure After AF Ablation
- OPTION in NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2408308
II. SUMMIT Trial
Tirzepatide Reduces Heart Failure Events in HFpEF With Obesity
- SUMMIT in NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2410027
III. VANISH Trial
New Trial Result Pushes Past Antiarrhythmic Therapy After MI
- VANISH 2 https://www.nejm.org/doi/full/10.1056/NEJMoa2409501
- VANISH 1 https://www.nejm.org/doi/full/10.1056/NEJMoa1513614
IV. Cardioprotection
Common Heart Failure Drugs Ease Heart Damage During Chemo https://www.medscape.com/viewarticle/common-heart-failure-drugs-ease-heart-damage-during-chemo-2024a1000l14
- Strain Imaging Review Article https://www.jacc.org/doi/10.1016/j.jcmg.2024.07.011
V. CLEAR trial
Spironolactone Shows Mixed Results in Acute MI
https://www.medscape.com/viewarticle/spironolactone-shows-mixed-results-acute-mi-2024a1000l41
Routine Colchicine or MRA Post-MI: No CLEAR Benefit
https://www.medscape.com/viewarticle/routine-colchicine-or-mra-post-mi-no-clear-benefit-2024a1000la2
- CLEAR-Spironolactone https://www.nejm.org/doi/full/10.1056/NEJMoa2405923
- CLEAR-Colchicine https://www.nejm.org/doi/full/10.1056/NEJMoa2405922
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net